Evidence map›Paper›PMID 42086408›Full record

ReviewTrends in molecular medicine2026

Targeting the NAD

Md Ibrahim, Md Shahadat Hossain, Lezanne Ooi, Md Mahmudul Hasan, Shandra Ahsan, Aliasger K Salem, Gary A Piazza, Xiaodong Feng, Fakhrul Ahsan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Md IbrahimDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA 95757, USA. Electronic address: md.ibrahim@cnsu.edu.
Md Shahadat HossainDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA 95757, USA.
Lezanne OoiSchool of Science and Molecular Horizons, University of Wollongong, Northfields Avenue, Wollongong, New South Wales 2522, Australia.
Md Mahmudul HasanDepartment of Pharmacy, University of Chittagong, Chittagong 4331, Bangladesh.
Shandra AhsanDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.
Aliasger K SalemDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.
Gary A PiazzaDrug Discovery and Development Department, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
Xiaodong FengDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA 95757, USA.
Fakhrul AhsanVeterans Affairs Northern California Health Care System, Martinez, CA 94553, USA; School of Computer, Mathematical and Natural Sciences, Morgan State University, Baltimore, MD 21251, USA. Electronic address: fakhrul.ahsan@morgan.edu.

Funding

Recapitulation of sex- disparity in PAH on a microfluidic device and elucidation of the differences and similarities in the development, progression and therapy of PAH in male versus female patientsR01HL144590 · NHLBI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI AHSAN, FAKHRUL · 2019 to 2022
$1.7M
PAH-on-a-chip: a novel disease-on-a-device model for studying the pathobiology of and screening drugs for pulmonary arterial hypertensionR43HL169134 · NHLBI · MEDLUIDICS LLC · PI AHSAN, FAKHRUL · 2023 to 2024
$427k
NHLBI NIH HHS R01 HL144590NHLBI NIH HHS R43 HL169134
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) remains a fatal neurodegenerative disease with few effective therapies. Emerging evidence indicates that oxidative DNA damage, defective base excision and single-strand break repair, and progressive NAD

Indexed as

amyotrophic lateral sclerosisDNA damage repairNAD(+) metabolismneuroprotectionPARP1 hyperactivationXRCC1 dysfunction

Identifiers

PMID42086408
PMCPMC13151995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.